Talking about the scoping study and recovery rates.
The importance of high recovery rates using HPAL cannot be overstated. The NPV due to capital cost is going to be a bummer in my view but if analysts see the recovery rates affording healthy feed stock then we get a big tick as @roblun has suggested numerous times.
Also if the NPV and IRR are not great the analysts should factor in the the other 50% of Mt Thirsty that GAL has.
I don't put much weight on the scandium and it is not included in this study anyway so the capital cost should not factor in a scandium circuit.
Ann: Addendum to 2023 Notice of Annual General Meeting, page-7
Add GSR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $16.47M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.2¢ | $14.89K | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 748905 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 40456 | 1 |
View Market Depth
| Last trade - 15.42pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.2¢ |
Change
0.001 ( 9.09 %) |
||||
| Open | High | Low | Volume | ||
| 1.2¢ | 1.2¢ | 1.2¢ | 37501 | ||
| Last updated 14.26pm 17/05/2024 ? | |||||
| GSR (ASX) Chart |